Literature DB >> 19646303

Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent L. major.

Hamid Daneshvar1, Richard Burchmore, Paul Hagan, R Stephen Phillips.   

Abstract

An attenuated line of Leishmania major (L. major H-line) has been established by culturing promastigotes in vitro under gentamicin pressure. A modification of the previously described method for the generation of attenuated L. major is described, giving rise to attenuated parasites after 8 rather than 12 subpassages. No lesions developed in BALB/c mice infected with L. major H-line, whereas L. major wild-type (WT) induced a Th2 like response with progressive lesions. Analysis of splenocyte IFN-gamma and IL-4 production following stimulation with promastigotes shows that the L. major H-line preferentially induces Th1-like responses and possibly down-regulates Th2 responses in BALB/c mice. L. major H-line parasites remained localized in the skin and draining lymph node, whereas L. major WT parasites disseminated into the visceral organs of BALB/c mice. Mice infected with L. major H-line acquired some resistance against L. major WT. These results show that the attenuated cell line of L. major is not only avirulent but that it may also modulate the host immune response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19646303     DOI: 10.1017/S0031182009990679

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  8 in total

1.  Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.

Authors:  William R Ravis; Alejandro Llanos-Cuentas; Nestor Sosa; Mara Kreishman-Deitrick; Karen M Kopydlowski; Carl Nielsen; Kirsten S Smith; Philip L Smith; Janet H Ransom; Yuh-Jing Lin; Max Grogl
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

2.  Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis.

Authors:  Yanhua Li; Yunfeng Xiao; Mingquan Su; Rong Zhang; Jianbing Ding; Xiaoke Hao; Yueyun Ma
Journal:  Exp Ther Med       Date:  2015-11-18       Impact factor: 2.447

3.  Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.

Authors:  Néstor Sosa; Zeuz Capitán; Javier Nieto; Melissa Nieto; José Calzada; Hector Paz; Carmenza Spadafora; Mara Kreishman-Deitrick; Karen Kopydlowski; Diane Ullman; William F McCarthy; Janet Ransom; Jonathan Berman; Charles Scott; Max Grogl
Journal:  Am J Trop Med Hyg       Date:  2013-07-15       Impact factor: 2.345

4.  Protective immunity and vaccination against cutaneous leishmaniasis.

Authors:  Ifeoma Okwor; Zhirong Mou; Dong Liu; Jude Uzonna
Journal:  Front Immunol       Date:  2012-05-29       Impact factor: 7.561

5.  Th9/IL-9 profile in human echinococcosis: their involvement in immune response during infection by Echinococcus granulosus.

Authors:  Nannan Pang; Fengbo Zhang; Xiumin Ma; Zhaoxia Zhang; Hui Zhao; Yan Xin; Song Wang; Yuejie Zhu; Hao Wen; Jianbing Ding
Journal:  Mediators Inflamm       Date:  2014-03-30       Impact factor: 4.711

6.  Parasite load decrease during application of a safe and easily applied antileishmanial aminoglycoside cream.

Authors:  Afif Ben Salah; Amor Zaâtour; Nathalie Ben Messaoud; Abdelhamid Kidar; Philip L Smith; Karen M Kopydlowski; Mara Kreishman-Deitrick; Carl J Nielsen; Anne Novitt-Moreno; Janet H Ransom; Gloria Morizot; Max Grogl; Pierre A Buffet
Journal:  PLoS Negl Trop Dis       Date:  2014-05-22

Review 7.  Live vaccination tactics: possible approaches for controlling visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahareh Taheri; Sima Rafati
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

8.  CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells are positively correlated with levels of IL-21 in active and transitional cystic echinococcosis patients.

Authors:  Fengbo Zhang; Nannan Pang; Yuejie Zhu; Dexian Zhou; Hui Zhao; Jinwei Hu; Xiumin Ma; Jun Li; Hao Wen; Buka Samten; Haining Fan; Jianbing Ding
Journal:  BMC Infect Dis       Date:  2015-10-26       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.